Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 268

1.

Triple-negative/basal-like breast cancer: review.

Rakha EA, Ellis IO.

Pathology. 2009 Jan;41(1):40-7. doi: 10.1080/00313020802563510. Review.

PMID:
19089739
2.

Triple negative tumours: a critical review.

Reis-Filho JS, Tutt AN.

Histopathology. 2008 Jan;52(1):108-18. doi: 10.1111/j.1365-2559.2007.02889.x. Review.

PMID:
18171422
3.

Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice.

Diaz LK, Cryns VL, Symmans WF, Sneige N.

Adv Anat Pathol. 2007 Nov;14(6):419-30. Review.

PMID:
18049131
4.

What is triple-negative breast cancer?

Irvin WJ Jr, Carey LA.

Eur J Cancer. 2008 Dec;44(18):2799-805. doi: 10.1016/j.ejca.2008.09.034. Epub 2008 Nov 12. Review.

PMID:
19008097
5.

Pharmacotherapy of triple-negative breast cancer.

Arslan C, Dizdar O, Altundag K.

Expert Opin Pharmacother. 2009 Sep;10(13):2081-93. doi: 10.1517/14656560903117309. Review.

PMID:
19640211
6.

Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.

Liu H, Fan Q, Zhang Z, Li X, Yu H, Meng F.

Hum Pathol. 2008 Feb;39(2):167-74. Epub 2007 Nov 28.

PMID:
18045647
7.

Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features.

Venkitaraman R.

Expert Rev Anticancer Ther. 2010 Feb;10(2):199-207. doi: 10.1586/era.09.189. Review.

PMID:
20131996
8.

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.

Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO.

Clin Cancer Res. 2008 Mar 1;14(5):1368-76. doi: 10.1158/1078-0432.CCR-07-1658.

9.

Is triple negative a prognostic factor in breast cancer?

Nishimura R, Arima N.

Breast Cancer. 2008;15(4):303-8. doi: 10.1007/s12282-008-0042-3. Epub 2008 Mar 29.

PMID:
18369692
10.

Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics.

Kurebayashi J.

Breast Cancer. 2009;16(4):275-80. doi: 10.1007/s12282-009-0111-2. Epub 2009 May 1.

PMID:
19408071
11.

Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society.

Iwase H, Kurebayashi J, Tsuda H, Ohta T, Kurosumi M, Miyamoto K, Yamamoto Y, Iwase T.

Breast Cancer. 2010 Apr;17(2):118-24. doi: 10.1007/s12282-009-0113-0. Epub 2009 May 23.

PMID:
19466512
12.

Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists.

Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR, Palacios J, Rakha EA, Richardson AL, Schmitt FC, Tan PH, Tse GM, Weigelt B, Ellis IO, Reis-Filho JS.

Mod Pathol. 2011 Feb;24(2):157-67. doi: 10.1038/modpathol.2010.200. Epub 2010 Nov 12. Review.

13.

Clinical significance of basal-like subtype in triple-negative breast cancer.

Yamamoto Y, Ibusuki M, Nakano M, Kawasoe T, Hiki R, Iwase H.

Breast Cancer. 2009;16(4):260-7. doi: 10.1007/s12282-009-0150-8. Epub 2009 Aug 22.

PMID:
19701681
14.

Lymphatic and blood vessels in basal and triple-negative breast cancers: characteristics and prognostic significance.

Mohammed RA, Ellis IO, Mahmmod AM, Hawkes EC, Green AR, Rakha EA, Martin SG.

Mod Pathol. 2011 Jun;24(6):774-85. doi: 10.1038/modpathol.2011.4. Epub 2011 Mar 4.

15.

Morphological characteristics of basal-like subtype of breast carcinoma with special reference to cytopathological features.

Ishihara A, Tsuda H, Kitagawa K, Yoneda M, Shiraishi T.

Breast Cancer. 2009;16(3):179-85. doi: 10.1007/s12282-009-0108-x. Epub 2009 May 23.

PMID:
19466513
16.

What is the difference between triple-negative and basal breast cancers?

Seal MD, Chia SK.

Cancer J. 2010 Jan-Feb;16(1):12-6. doi: 10.1097/PPO.0b013e3181cf04be. Review.

PMID:
20164685
17.

Metastatic triple-negative breast cancer.

Rakha EA, Chan S.

Clin Oncol (R Coll Radiol). 2011 Nov;23(9):587-600. doi: 10.1016/j.clon.2011.03.013. Epub 2011 Apr 23. Review.

PMID:
21524569
18.

Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research.

Bosch A, Eroles P, Zaragoza R, Viña JR, Lluch A.

Cancer Treat Rev. 2010 May;36(3):206-15. doi: 10.1016/j.ctrv.2009.12.002. Epub 2010 Jan 8. Review.

PMID:
20060649
19.

Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients.

Tan DS, Marchió C, Jones RL, Savage K, Smith IE, Dowsett M, Reis-Filho JS.

Breast Cancer Res Treat. 2008 Sep;111(1):27-44. Epub 2007 Oct 6.

PMID:
17922188
20.

Impact of basal-like breast carcinoma determination for a more specific therapy.

Rakha EA, Reis-Filho JS, Ellis IO.

Pathobiology. 2008;75(2):95-103. doi: 10.1159/000123847. Epub 2008 Jun 10. Review.

PMID:
18544964

Supplemental Content

Support Center